Does OptumRx Cover Wegovy? 2025 Formulary Guidelines

OptumRx and UnitedHealthcare Prescription Drug Management

OptumRx functions as the pharmacy benefit manager (PBM) for UnitedHealth Group, setting formulary placement and evaluating prior authorization requests for UnitedHealthcare commercial and Medicare plans. OptumRx decides which medications appear on standard formulary tiers, what clinical criteria patients must meet, and which drugs require prior authorization.

For members with UnitedHealthcare coverage, OptumRx processes all pharmacy claims and evaluates coverage appeals. Plan designs vary between large employer groups, individual health plans, and government programs. For an analysis of how OptumRx handles related glucagon-like peptide-1 (GLP-1) receptor agonists, review our guide to UnitedHealthcare Ozempic coverage.

UnitedHealthcare owns OptumRx, but your individual plan sponsor decides whether to fund optional drug categories like weight loss. That division of responsibility explains why two workers with OptumRx cards can receive entirely different coverage decisions for the exact same prescription.

Approved Medical Indications for Wegovy

The Food and Drug Administration (FDA) approves Wegovy for two distinct clinical uses: chronic weight management in qualifying adults and major cardiovascular event risk reduction in adults with established heart disease.

The initial approval covers chronic weight management in adults with a baseline Body Mass Index (BMI) of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater with at least one weight-related condition such as hypertension, type 2 diabetes, or dyslipidemia. In March 2024, the FDA approved a supplemental indication for Wegovy. This second approval allows prescribers to use Wegovy to reduce the risk of cardiovascular death, heart attack, and stroke in adults who have established cardiovascular disease and are either obese or overweight.

Patients comparing treatment options can examine our analysis of Wegovy vs Zepbound to see how these clinical indications and trial outcomes compare across agents. This dual-indication status fundamentally reshaped how pharmacy benefit managers handle formulary placement.

How Does OptumRx Cover Wegovy Under 2025 Guidelines

OptumRx updated its published 2025 Premium Standard Formulary to add Wegovy specifically for cardiovascular risk reduction rather than general weight loss.

This policy shift followed the March 2024 FDA approval for cardiovascular protection. Under published OptumRx 2025 formulary guidelines, commercial plans that do not include general weight-loss coverage are still required to cover Wegovy when prescribed to reduce cardiovascular event risks in eligible patients.

If you review the OptumRx formulary booklet, you will find Wegovy listed with an indication-specific restriction. The listing does not signify universal coverage for obesity. It establishes that patients with documented cardiovascular disease have a recognized coverage pathway even if their employer excluded anti-obesity drugs from their healthcare package.

Why Weight Loss Prescriptions Trigger Plan Denials

Prescriptions written exclusively for obesity or chronic weight management receive claim denials when an employer group excludes weight-loss drug benefits from its health plan.

Many employer-sponsored plans treat weight-loss medications as an optional benefit package. Employers choose whether to purchase an anti-obesity rider when designing employee health coverage. If an employer opts out of weight-loss benefits, OptumRx must deny claims submitted with primary obesity diagnostic codes.

A patient may see Wegovy on an OptumRx formulary search tool, assume it is covered, and receive a denial at the pharmacy counter. This occurs because the prescriber submitted an obesity code instead of documenting established cardiovascular disease, or because the employer selected a benefit design that excludes all anti-obesity treatments.

OptumRx Prior Authorization for Weight Loss

OptumRx Wegovy prior authorization for chronic weight management requires clinical verification of qualifying baseline body mass index measurements and past lifestyle modification efforts.

When an employer includes the weight-management benefit rider, approval is not automatic. Prescribers must submit a detailed prior authorization request demonstrating that the patient meets FDA label standards. The medical record must document a BMI of 30 kg/m² or greater, or a BMI of 27 kg/m² or greater accompanied by a weight-related comorbidity such as high blood pressure or dyslipidemia.

In addition to BMI thresholds, OptumRx prior authorization criteria commonly require documentation showing that the patient attempted a structured nutritional and physical activity program before initiating pharmacotherapy. Initial coverage approvals typically cover a six to twelve month period. To qualify for reauthorization, clinical documentation must confirm sustained weight reduction, usually defined as losing at least 5% of baseline body weight during the initial treatment window.

Medicare Coverage Under the GLP-1 Bridge Program

UnitedHealthcare Medicare Advantage and Part D members can access Wegovy for chronic weight management through the federal Medicare GLP-1 Bridge program beginning July 1, 2026.

Medicare Part D historically excluded medications prescribed solely for weight loss due to federal statutory limitations. To address affordability and clinical access, the Centers for Medicare & Medicaid Services (CMS) established a demonstration project running from July 1, 2026 through December 31, 2027. Under this CMS pilot, participating Medicare Part D plans, including UnitedHealthcare plans administered by OptumRx, provide Wegovy, Foundayo tablets, and the Zepbound KwikPen for chronic weight management at a fixed $50 monthly copayment.

This $50 copay does not count toward the annual Part D deductible or the $2,100 out-of-pocket maximum established for 2026 Part D benefit years. This federal initiative functions independently of standard employer plan rules and provides a dedicated pathway for Medicare enrollees who lack commercial coverage options.

Resolving Prior Authorization Denials

Resolving an OptumRx Wegovy denial requires identifying whether the rejection stemmed from an excluded plan benefit or an incorrect medical diagnosis code.

If your prescription was denied, request a copy of the formal explanation of benefits from OptumRx. When a denial indicates that weight-loss medications are an excluded category, submitting an appeal based on obesity alone will rarely succeed. You must demonstrate that the plan terms permit the benefit or that the diagnosis falls under a covered category.

If you have a documented history of cardiovascular conditions such as previous myocardial infarction, stroke, or peripheral artery disease, your prescriber can submit a revised prior authorization request under the cardiovascular-risk-reduction indication. Documenting this history allows OptumRx to process the claim under the standard formulary rules rather than the excluded weight-loss category.

When Does OptumRx Cover Wegovy Without Weight Loss Riders

Patients who lack both established cardiovascular disease and employer-sponsored weight-loss coverage cannot obtain standard OptumRx approval for Wegovy.

This coverage boundary applies to millions of commercial plan members who seek Wegovy for weight reduction without documented cardiovascular pathology. In those situations, discuss generic oral alternatives with your clinician or explore manufacturer savings arrangements to manage therapy costs.

Several developments could alter this coverage environment. If an employer modifies its contract during an open enrollment period to add anti-obesity coverage, weight-loss authorization becomes attainable. If CMS elects to expand or make permanent the Medicare GLP-1 Bridge model after 2027, Medicare access rules could shift across broader populations.

Verifying Your Specific OptumRx Formulary

Confirming your pharmacy benefits directly through the OptumRx member portal prevents delays and unexpected expenses before you visit your prescriber.

Check your specific plan details by completing these steps:

• Log into your OptumRx or UnitedHealthcare member account and navigate to the drug pricing tool to check whether Wegovy is listed under your specific plan.
• Review your plan's Evidence of Coverage document to verify whether weight-loss medications are an included category or an excluded benefit.
• Ask your doctor to check your medical record for documented cardiovascular disease if your plan covers only the cardiovascular-risk pathway.
• Contact OptumRx member services directly to ask whether prior authorization criteria require specific step-therapy trials or baseline BMI documentation.

Taking these steps ensures you enter your clinical appointment with complete information about your benefit design. Before scheduling an appointment with your prescriber, call member services to verify your plan documents and confirm how your policy answers does OptumRx cover Wegovy.

What to Look For in a Body-Composition Scale

A bioimpedance scale trends body fat and muscle rather than just weight — useful when the number stalls but your composition is improving. The absolute body-fat % isn't lab-accurate, so use it for TRENDS at a consistent time of day. Choose one that syncs to an app so you can watch the trend line.

GE Smart Scale for Body Weight: 8-Electrode Digital Bathroom Scale for Weight Fat BMI Muscle Mass Full Body Composition Analyzer 50 Measurements Bluetooth Highly Accurate Weighing Machine 400lb Black

GE

View on Amazon →

Etekcity Smart Scale for Body Weight, FSA&HSA Eligible, Bathroom Digital Weighing Scale with BMI, Body Fat, Muscle Mass, Accurate Bluetooth Home User Health Equipment Sync Apps, LED, Tempered glass

Etekcity

View on Amazon →